NOT FOR DISTRIBUTION
Header cover image

Market Cap

AU$84.8m

Last Updated

2021/04/12 08:22 UTC

Data Sources

Company Financials +

Executive Summary

OncoSil Medical Limited, a medical device company, focuses on the development of localized treatments for pancreatic and liver cancer in Australia. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has OncoSil Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OSL is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: OSL's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

6.4%

OSL

0.9%

AU Life Sciences

2.6%

AU Market


1 Year Return

-20.0%

OSL

38.3%

AU Life Sciences

37.1%

AU Market

Return vs Industry: OSL underperformed the Australian Life Sciences industry which returned 38.3% over the past year.

Return vs Market: OSL underperformed the Australian Market which returned 37.1% over the past year.


Shareholder returns

OSLIndustryMarket
7 Day6.4%0.9%2.6%
30 Day1.0%-3.1%3.3%
90 Day-20.0%-4.6%4.6%
1 Year-18.4%-20.0%38.5%38.3%41.3%37.1%
3 Year-24.5%-25.9%45.4%38.2%36.2%19.8%
5 Year-38.2%-39.4%-13.4%-25.6%67.4%34.6%

Long-Term Price Volatility Vs. Market

How volatile is OncoSil Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is OncoSil Medical undervalued compared to its fair value and its price relative to the market?

4.79x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OSL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OSL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OSL is unprofitable, so we can't compare its PE Ratio to the XX Life Sciences industry average.

PE vs Market: OSL is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OSL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OSL is good value based on its PB Ratio (4.8x) compared to the AU Life Sciences industry average (5.1x).


Future Growth

How is OncoSil Medical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-5.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OSL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OSL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OSL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OSL's revenue is expected to decline over the next 3 years (-47.3% per year).

High Growth Revenue: OSL's revenue is forecast to decline over the next 3 years (-47.3% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OSL is forecast to be unprofitable in 3 years.


Past Performance

How has OncoSil Medical performed over the past 5 years?

-5.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OSL is currently unprofitable.

Growing Profit Margin: OSL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OSL is unprofitable, and losses have increased over the past 5 years at a rate of 5.1% per year.

Accelerating Growth: Unable to compare OSL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OSL is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (36.2%).


Return on Equity

High ROE: OSL has a negative Return on Equity (-32.9%), as it is currently unprofitable.


Financial Health

How is OncoSil Medical's financial position?


Financial Position Analysis

Short Term Liabilities: OSL's short term assets (A$18.9M) exceed its short term liabilities (A$2.0M).

Long Term Liabilities: OSL has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: OSL is debt free.

Reducing Debt: OSL had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OSL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: OSL has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 14.5% each year


Dividend

What is OncoSil Medical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OSL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OSL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OSL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OSL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OSL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.7yrs

Average management tenure


CEO

Nigel Lange

0.25

Tenure

Mr. Nigel Lange serves as Chief Executive officer and Managing Director of OncoSil Medical Limited since January 21, 2021. He serves as President of EMEA at OncoSil Medical Limited since May 2020. He serve...


Leadership Team

Experienced Management: OSL's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: OSL's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 30.1%.


Top Shareholders

Company Information

OncoSil Medical Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OncoSil Medical Limited
  • Ticker: OSL
  • Exchange: ASX
  • Founded: 2005
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$84.771m
  • Shares outstanding: 807.34m
  • Website: https://www.oncosil.com.au

Location

  • OncoSil Medical Limited
  • 15 Blue Street
  • Suite 503
  • North Sydney
  • New South Wales
  • 2060
  • Australia

Listings


Biography

OncoSil Medical Limited, a medical device company, focuses on the development of localized treatments for pancreatic and liver cancer in Australia. Its lead product is OncoSil, a brachytherapy device that ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/12 08:22
End of Day Share Price2021/04/12 00:00
Earnings2020/12/31
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.